BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 18185020)

  • 1. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
    Basaran M; Bavbek ES; Saglam S; Eralp L; Sakar B; Atalar AC; Bilgic B; Ozger H; Onat H
    Oncology; 2007; 72(3-4):255-60. PubMed ID: 18185020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
    Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
    Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
    Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
    Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
    Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
    Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
    Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
    Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study.
    Arpaci F; Ataergin S; Ozet A; Erler K; Basbozkurt M; Ozcan A; Komurcu S; Ozturk B; Celasun B; Kilic S; Kuzhan O
    Cancer; 2005 Sep; 104(5):1058-65. PubMed ID: 15999369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
    Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
    Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood osteosarcoma: multimodal therapy in a single-institution Turkish series.
    Ayan I; Kebudi R; Ozger H
    Cancer Treat Res; 2009; 152():319-38. PubMed ID: 20213399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
    Bacci G; Ferrari S; Tienghi A; Bertoni F; Mercuri M; Longhi A; Fiorentini G; Forni C; Bacchini P; Rimondini S; De Giorgi U; Picci P
    Eur J Surg Oncol; 2001 Feb; 27(1):98-104. PubMed ID: 11237499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant treatment in osteosarcomas].
    Kalifa C; Brugières L; Le Deley MC
    Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.